6-溴-7-[11C]甲基嘌呤的首次人体评估:一种用于评估不同组织中多药耐药相关蛋白功能的PET示踪剂
研究纳入13名健康志愿者(7男6女),在长轴视野PET/CT系统上静脉注射[11C]BMP后进行动态全身PET扫描,其中每性别3人重复扫描以评估可重复性。结果显示各组织kE均值及重测变异度在可接受范围(视网膜除外),男性有效剂量4.67±0.18 µSv/MBq、女性4.55±0.18 µSv/MBq,LAFOV PET/CT有望同时评估多组织MRP功能。
要点
- 13名健康志愿者接受[11C]BMP动态全身PET/CT,每性别3人重复扫描评估可重复性。
- 各组织kE重测变异度在可接受范围,但视网膜为30±38%。
- 有效剂量男性4.67±0.18 µSv/MBq、女性4.55±0.18 µSv/MBq,属11C示踪剂典型范围。
核心结论
- LAFOV PET/CT联合[11C]BMP有望同时评估多个人类组织中的MRP功能。
- 不同组织kE的平均重测变异度在可接受范围内,但视网膜除外。
- [11C]BMP的辐射剂量学处于11C示踪剂的典型范围。
- LAFOV PET/CT在全身、多组织层面评估与人体药物处置相关的分子靶点方面具有很大潜力。
研究设计与样本
- 首次人体研究,纳入13名健康志愿者(7名男性、6名女性)。
- 静脉注射[11C]BMP后在长轴视野(LAFOV)PET/CT系统上进行动态全身PET扫描。
- 每性别3名受试者进行第二次扫描以评估可重复性。
- 勾画MRP表达组织(大脑皮层、小脑、脉络丛、视网膜、肺、心肌、肾和肝)的感兴趣体积。
- 从时间-放射性曲线推导消除速率常数(kE,h⁻¹)作为组织MRP功能参数,并计算其重测变异度(TRTV,%)。
主要发现
- 大脑皮层kE为0.055±0.010 h⁻¹,TRTV为-4±24%。
- 小脑kE为0.033±0.009 h⁻¹,TRTV为1±39%。
- 脉络丛kE为0.292±0.059 h⁻¹,TRTV为0.1±16%。
- 视网膜kE为0.234±0.045 h⁻¹,TRTV为30±38%。
- 肺kE为0.875±0.095 h⁻¹,TRTV为-3±11%。
关键数值与推荐
- 以消除速率常数kE(h⁻¹)作为组织MRP功能的参数。
- 以重测变异度(TRTV,%)评估kE的可重复性。
- 采用MIRD方法计算辐射剂量学。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不同组织kE的平均重测变异度在可接受范围内,但视网膜除外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer's and chronic respiratory disease. PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) has been used to measure MRP1 function in rodents. In this study, [11C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues. METHODS: Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [11C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant (kE, h- 1) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology. RESULTS: Mean kE and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h- 1 (- 4 ± 24%), cerebellum: 0.033 ± 0.009 h- 1 (1 ± 39%), choroid plexus: 0.292 ± 0.059 h- 1 (0.1 ± 16%), retina: 0.234 ± 0.045 h- 1 (30 ± 38%), lungs: 0.875 ± 0.095 h- 1 (- 3 ± 11%), myocardium: 0.641 ± 0.105 h- 1 (11 ± 25%), kidneys: 1.378 ± 0.266 h- 1 (14 ± 16%), and liver: 0.685 ± 0.072 h- 1 (7 ± 9%). Significant sex differences were found for kE in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women. CONCLUSION: LAFOV PET/CT with [11C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of kE in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [11C]BMP was in the typical range of 11C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans. TRIAL REGISTRATION: EudraCT 2021-006348-29. Registered 15 December 2021.
引用
- Mairinger S, Jackwerth M, Chalampalakis Z, et al. First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues. Eur J Nucl Med Mol Imaging. 2024. PMID: 39060376. doi:10.1007/s00259-024-06851-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。